From June 24 to 26, 2022, the assessment team from the China National Accreditation Service for Conformity Assessment (abbreviated as CNAS in English) conducted an expanded scope review of Suzhou Xishan Biotechnology Co., Ltd.

Image Name

2022.06.24

To promote the strengthening of conformity assessment bodies in accordance with relevant standards and regulations, the China National Accreditation Service for Conformity Assessment (CNAS) evaluation team conducted an expanded scope review of Suzhou Xishan Biotechnology Co., Ltd. from June 24 to 26, 2022. During this review, the team thoroughly assessed the effectiveness, compliance, and adaptability of our company’s management system through on-site inspections, inquiries, practical testing, as well as by examining reports, records, and archives.

The review for Japan concluded successfully, and the company has now added CNAS accreditation for routine testing items such as mouse adenovirus, Japanese encephalitis virus type B, Escherichia coli, and Streptococcus pneumoniae.

West Mountain

Previous article

From September 19 to September 21, 2022, the assessment team from the China National Accreditation Service for Conformity Assessment (referred to as CNAS in English) conducted a specialized laboratory supervision review of Suzhou Xishan Biotechnology Co., Ltd.

On June 17, 2022, the Suzhou Municipal Bureau of Agriculture and Rural Affairs conducted a "Preliminary Review of Biosafety" at Xishan Biotechnology Co., Ltd.

Next article

Previous article

On June 17, 2022, the Suzhou Municipal Bureau of Agriculture and Rural Affairs conducted a "Preliminary Review of Biosafety" at Xishan Biotechnology Co., Ltd.

Next article

On June 17, 2022, the Suzhou Municipal Bureau of Agriculture and Rural Affairs conducted a "Preliminary Review of Biosafety" at Xishan Biotechnology Co., Ltd.

More information

On May 10, 2025, our company's Nanoyuan facility successfully completed the filing process for the Suzhou P2 laboratory, becoming one of the first organizations in Suzhou city to receive official accreditation.

On May 10, 2025, our company's Nanoyuan facility successfully completed the filing process for the Suzhou P2 laboratory, becoming one of the first organizations in Suzhou city to receive official accreditation.

[Suzhou, May 10, 2025] Recently, our company’s Nano Park facility successfully completed the filing process for its P2 laboratory with the Suzhou Municipal Bureau of Agriculture and Rural Affairs, officially becoming one of the first animal pathogen microbiology laboratories in the entire Suzhou metropolitan area to receive approval under the newly implemented "Jiangsu Province Animal Pathogen Microbiology Laboratory Filing Management Measures" (effective February 1, 2025).

From September 1 to 2, 2024, our company successfully passed the CMA on-site assessment, further solidifying the authoritative recognition of our capabilities in laboratory animal testing.

From September 1 to 2, 2024, our company successfully passed the CMA on-site assessment, further solidifying the authoritative recognition of our capabilities in laboratory animal testing.

Recently, our company successfully passed the on-site expansion review for CMA accreditation, marking official recognition from a national authority of our professional expertise and robust quality management system in the field of laboratory animal testing. The review took place from September 1 to September 2, 2024, during which the expert panel conducted a comprehensive and rigorous assessment of our laboratory animal testing technologies, equipment, personnel, and management systems—ultimately confirming that we meet the relevant CMA standards.

August 6, 2024: Warmest congratulations to our company on successfully obtaining the veterinary drug production license and the veterinary drug GMP certificate.

August 6, 2024: Warmest congratulations to our company on successfully obtaining the veterinary drug production license and the veterinary drug GMP certificate.

August 6, 2024 – Our company has officially obtained the Veterinary Drug Production License and the Veterinary Drug GMP Certificate issued by the Ministry of Agriculture and Rural Affairs, marking that our company’s quality management system and technical capabilities in the veterinary drug manufacturing sector have met the nation’s stringent high-standard requirements. During this certification process, our immunology-based diagnostic product (Class B) production line successfully passed the on-site GMP inspection for veterinary drugs and was recognized as a qualified production line, laying a solid foundation for the company to further expand into the veterinary diagnostic reagent market.